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Objectives: Insight into healthcare professionals’
views and experiences of the use of ciclosporin and
infliximab as salvage therapies for acute ulcerative
colitis (UC) and how this may affect participation in a
comparison trial is lacking. The study aimed to capture
views and opinions of healthcare professionals about
the two drugs within the CONSTRUCT trial.
Design: An interview-based qualitative study using
Framework Analysis embedded within an open-label,
pragmatic randomised trial.
Setting: National Health Service Health Boards and
Trusts, including large teaching and district hospitals in
England, Scotland and Wales.
Participants: Principal Investigators (PIs) for trial
sites (who were all consultant gastroenterologists) and
nurses responsible for administering and monitoring
the salvage therapy drugs across trial sites. 15 PIs and
8 nurses recruited from a range of sites stratified by
site recruitment rates were interviewed.
Results: Interviews revealed that professionals made
judgements regarding the salvage therapies largely
based on experience of giving the two drugs and
perceptions of effectiveness and adverse side effects.
A clear preference for infliximab among nurses was
revealed, largely based on experiences of
administration and drug handling, with some doctors
strongly favouring infliximab based on experience of
prescribing the drug as well as patient views and the
existing evidence base. Most doctors were more
equivocal, and all were prepared to suspend
preferences and wait for evidence of effectiveness and
safety from the CONSTRUCT trial. PIs also questioned
guidelines around drug use and restrictions placed on
personal autonomy in delivering best patient care.
Conclusions: Findings highlight healthcare
professionals’ preference for the salvage treatment,
infliximab in treating steroid-resistant UC, largely based
on resource intensive nursing requirements of
intravenous administration of ciclosporin. Not all
doctors expressed this preference, being more
equivocal, and all professionals were content to
suspend preferences within the CONSTRUCT trial and
recognised the importance of establishing relative
effectiveness and safety.
Trial registration number: ISRCTN 22663589.
BACKGROUND
Ulcerative colitis (UC) is a chronic debilitat-
ing disease which affects ∼150 000 people in
the UK.1 In many cases, UC presents as
acute severe colitis requiring patient hospital-
isation;2 however, there are unanswered ques-
tions regarding causes, course, treatments
and outcomes, despite rapidly developing
new therapies. The standard approach to
treatment is administration of intravenous
steroids, but about 40% of patients fail to
respond to this.3 4 Until recently, emergency
colectomy remained the only option when
steroids fail, with a high mortality rate.5
While there are now a range of other treat-
ments, and mortality following colectomy has
dramatically reduced, 10% of patients still
die within 3 months of surgery.5
Strengths and limitations of this study
▪ The first study that has successfully incorporated
qualitative data into a clinical trial to explore pro-
fessional equipoise, preference and drug man-
agement for salvage therapy in patients with
ulcerative colitis who fail to respond to steroids.
▪ The study cannot make any claims about the
views of the full professional trial cohort but data
collected can reveal current trends in practice
and professional opinion to inform service devel-
opment and future drug use.
▪ Interview data, as an integral part of trial find-
ings, provided insight into factors influencing
trial treatment preferences and addressed issues
of equipoise within the trial.
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Inﬂiximab and ciclosporin are immunosuppressant
drugs that offer hope for the treatment of
steroid-resistant UC. There is evidence that both are
effective in the shorter term,6 7 but questions remain
over their longer term clinical use and cost-effectiveness
and little is known of the views and experiences of
patients and clinicians regarding the two drugs.
The ‘Comparison Of iNﬂiximab and ciclosporin in
STeroid resistant Ulcerative Colitis: a Trial’ (The
CONSTRUCT trial) aimed to compare the clinical and
cost-effectiveness of inﬂiximab and ciclosporin for
patients with steroid-resistant UC using quantitative,
qualitative, health economic and data-linkage research
methods8 9 in a multicentre UK-wide pragmatic rando-
mised controlled trial. Following explanation and
consent, 1614 patients who were admitted with acute
severe UC were recruited into a cohort from which 270
who failed to respond to intravenous steroids were
recruited into the trial. The trial recruited patients from
52 hospitals between May 2010 and February 2013, and
investigated differences between the two drug treatments
in terms of: patient health-related quality of life, adverse
events, mortality, disease activity, colectomy rates and
cost-effectiveness. Additionally, the trial aimed to enrich
trial ﬁndings and reporting of treatment delivery
context by seeking the views and experiences of patients
about treatments and changes to health over time, and
the opinions of healthcare professionals about drug out-
comes, ease of drug handling and drug preference. The
CONSTRUCT Trial Management Team was also aware
that potential treatment preferences within trial health-
care professionals could inﬂuence recruitment to the
trial10 and therefore sought to also explore this within
healthcare professional interviews.
It is important to understand context of delivery, im-
plementation, perceived outcomes and treatment prefer-
ence in order to fully understand and report pragmatic
trials.10 11 Through understanding how the investigative
drugs are managed and perceived, trial ﬁndings become
more patient centred and sensitive to the context of
practice. What little insightful experience-based research
is reported in the literature on ciclosporin or inﬂiximab
focuses on inﬂiximab’s role in treating rheumatoid arth-
ritis.12 There are no studies exploring the use of ciclos-
porin in the treatment of acute UC and what people’s
experiences and perceptions are of this treatment. One
qualitative study exploring patient and parent experi-
ences of inﬂiximab in gastroenterology paediatric set-
tings found favourable views of the drug when used in a
hospital environment.12 However, to the best of the
authors’ knowledge, no studies, qualitative or otherwise,
have explored health professionals’ views of these drugs
in terms of their administration, ease of handling or
value for treating steroid-resistant UC. This is somewhat
surprising, in view of the fact that qualitative methods
are particularly well suited to the investigation of per-
sonal experience, individual perception and belief and
meaning systems13 14 and can enable researchers to
clarify patients’ and clinicians’ understandings of clinical
practice and drug regimes. This is particular pertinent
to trials where such views and experiences can inﬂuence
trial conduct.15 16
In the light of the lack of current understanding and
an awareness of the importance of drug preference,
delivery context and drug management practices within
the CONSTRUCT trial, it was deemed vital to seek both
patients and healthcare professionals’ opinions. This
paper focuses solely on the professional views, while
patient views and experiences are presented elsewhere.9
Study aims and objectives
The study aimed to gain insight into the views and opi-
nions of healthcare professionals about the drugs being
tested in the CONSTRUCT trial (ie, inﬂiximab and
ciclosporin) and their personal contribution to the trial.
Speciﬁc objectives were to examine how drugs were
administered, their perceived ease of handling, profes-
sionals’ personal drug preferences and views on collea-
gues’ drug preferences, and equipoise in recruiting to
the trial.
METHODS
An interview-based qualitative study was embedded
within an open-label, pragmatic randomised trial.
Participants
Principal Investigators (PIs) for trial sites (who were all
consultant gastroenterologists) and nurses responsible
for administering and monitoring the drugs across trial
sites were included in the interview cohort.
Multidisciplinary team views would offer insights into
drug administration and personal preferences, and
clarify professionals’ opinions of the physical effects of
both drugs on patients and trial participation. A purpos-
ive sampling method was employed to select PIs for
interview, based on recruitment performance of sites:
recruiting well to cohort and trial; recruiting well to
cohort but less well to trial; and those recruiting poorly
to both the cohort and the trial. Nurses were only
recruited from sites recruiting well to cohort and trial,
in recognition of the fact that other nurses would have
had little relevant experience with one or other of the
two trial drugs.
Interviews
The PIs and nurses were approached via email or
phone, and were provided with information about the
interview study including aims and topics to be discussed
during the interview. Participants gave informed consent
through email responses. Experienced qualitative
researchers (CC and AS) used a semistructured inter-
view approach, allowing interviewees to expand on
responses to questions and raise issues of importance.14
CC was not known to the participants before interviews
but AS had previous contact with them within the trial.
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The interview schedule covered: interviewees’ beliefs
and ways of working; aspects of drug provision that
affected preferences, ease of drug handling, effects of
drugs; patient interaction; professional communication;
views on other professionals’ response to drug provision,
and personal contributions to the trial, including issues
of equipoise (interview topic guide is available as online
supplementary material). Interviews were carried out
face to face or over the phone, and lasted between 30
and 40 min. PIs and nurses were interviewed separately
to ensure that an understanding could be gained of dif-
ferences between them. Interviews were audio recorded
and transcribed for analysis purposes. A pilot PI inter-
view was conducted to test the schedule and process.
Piloting resulted in no changes.
Analysis
Transcripts were analysed using ‘Framework Analysis’17
to develop a thematic template that linked data to study
aims and objectives and guide analysis. Framework ana-
lysis is a semistructured approach that, like generic the-
matic analysis, uses coding to conceptualise and classify
research data.18 Three qualitative researchers (CC, AS
and FR) individually coded transcripts as they were tran-
scribed, increasing analysts’ knowledge in an iterative
fashion as each new transcript was received and tran-
script data supporting the analysis framework were
added. The three then worked together to derive a
coding structure including essential and incidental
themes and their linked categories within the frame-
work. Continuing group work to reﬁne the framework
validated the process and ensured that major themes
retained their nuance and detail. The analysts moni-
tored the process throughout data collection and ana-
lysis until data saturation (when no new information was
revealed to further theme development or understand-
ing) was achieved.19 20 Data saturation was achieved fol-
lowing the completion of 23 interviews as agreed by the
research team.
FINDINGS
The interview cohort comprised 15 PIs (consultants)
and 8 nurses. The PI stratiﬁcation was as follows: eight
from sites recruiting well; four from sites recruiting well
to cohort but less well to trial and three from sites
recruiting poorly to both cohort and trial. The nurses
were all from high trial recruitment sites (the same sites
as the 8 PIs). Not all PIs agreed to participate, due to
busy work schedules. Those declining were from lower
recruiting trial sites.
Through the Framework Analysis, four main themes
emerged: (1) drug administration and management, (2)
personal preference and trial involvement, (3) policy
development and drug regulation and (4) patient
beneﬁt and negotiated care. Both PIs and nurses dis-
cussed all four themes to an extent with overlapping
views and experiences; however, it should be noted that
nurses’ views were largely based on experiences of
administration and drug handling. PIs views were largely
based on experience of prescribing the drug as well as
patient views and existing evidence base. Themes were
underpinned by a rich data set comprising: (1) descrip-
tions of the practicalities of administering and monitor-
ing the two drugs and (2) contextual factors inﬂuencing
professionals’ views of the effects of inﬂiximab and
ciclosporin on the alleviation of symptoms and on
patients’ quality of life. In addition, analysis helped
derive: (3) greater understanding of professional per-
sonal preference for one or other drug, (4) knowledge
of professional experience and entry into the trial, (5)
information about other healthcare professionals’ prac-
tices and (6) perspectives on current Government policy
regarding the regulation of drugs and views on National
Institute for Health and Care Excellence (NICE)
Guidelines.21 Underpinning all of this was an ongoing
concern for patients’ welfare, informed patient choice
and joint decision-making.
The main ﬁndings are described in detail below along-
side professionals’ verbatim quotations. All quotations
are numbered, refer to table 1, coded as ‘PI’ or ‘nurse’
and include indication of which trial recruitment
cohort.
Drug administration and management
PIs and nurses, when asked about the administration of
inﬂiximab and ciclosporin, were keen to point out that
consideration must be given to the administration
process as well as to the lead-up procedure: ‘workup to
treatment’ (PI, Recruiting well to cohort but less well to
trial). Patient workup was seen as a vitally important step
in administering the drugs. However, workup was said to
be something that was neither given enough consider-
ation within the drug guidelines, nor discussed in terms
of its effect on the rest of the administration process,
such as its effect on drug handling. Interviewees
described the workup as necessary for the provision of
inﬂiximab and ciclosporin in similar terms; however, fol-
lowing initial workup, administration of inﬂiximab was
much easier to handle than the administration activities
necessary for the provision of ciclosporin. First, there
was less to be concerned about during that period of
time and second, the process had less impact on work-
load, especially for nurses, while both drugs demanded
due care and attention. Attention to detail was described
according to: the careful mixing of drugs and other pre-
parations necessary for treatment, prescreening of
patients and patient preparedness for the intravenous
infusions. In this respect, ciclosporin was consistently
described as the more complicated of the two, with a
longer administration time (continuous infusion as
opposed to 2 hours for inﬂiximab) and with the need
for frequent changes of intravenous bags (inﬂiximab is a
one-off infusion). This had a knock-on effect on health-
care professionals’ work schedules: see Q1 and Q2.








Q1 It [ciclosporin] goes on over a longer period of time obviously, so the need [for
nurses] to continually make up bags over a longer period of time rather than
just the one off infusion. (PI) Recruiting well
Q2 It’s [ciclosporin] time consuming for the nurses and slightly messy…it’s
complicated and it’s work for the nursing staff. (PI) Recruiting well
Q3 Having to make it up [ciclosporin] every 6 hours is time consuming, changing
lines, always having two nurses to check it because the way the GI unit is
split…there’s a corridor between the two wards so obviously bed cover etc but
only to have one trained [nurse] each side is a bit difficult … geography of the
wards… we’ve no one else to check the drugs. (Nurse) Recruiting well
Q4 [Ciclosporin] is fairly cumbersome for both the staff and equally importantly for
patients because once you are tied to the drip and associated drip stand, it
restricts patients moving around. (PI) Recruiting well
Q5 Infliximab has an advantage (over ciclosporin) in that it’s just a two-hour
infusion and then it’s done… there’s no problem with infliximab, I think it’s a
good drug to administer, I think it’s an easy drug to administer… I like infliximab
because once you’ve done it, you’ve done it for 2 weeks. (PI) Recruiting well
Q6 Tend to use ciclosporin as acting more quickly. (PI) Recruiting well to cohort
but less well to RCT
Q7 This is the one thing I don’t like about infliximab, because there is no data to
give us a clear timescale or timeline for decision-making. (PI) Recruiting well
Q8 I’m always a little bit more nervous with it [ciclosporin] … and I think that’s from
the side effects of renal impairment … I think the side effects profile of
ciclosporin, still concerns us more. (PI) Recruiting well
Q9 Potentially quite significant side effects… slightly uncomfortable feeling about it
[ciclosporin]. (PI) Recruiting well
Q10 It’s [ciclosporin] time consuming with regards to observation, particularly on a
busy ward when you’ve got one nurse to 10 patients, it can take quite a huge
part of your workload. (Nurse) Recruiting well
Q11 We have to monitor this patient closely for any side effects… it [ciclosporin]
takes three hours because you’ve got to do obs [observations] for a couple of
hours, but then sometimes we tend to forget because we get busy with other
patients … so ideally it should be one to one. (Nurse) Recruiting well
Q12 Most of the time it [infliximab] goes without incident. (Nurse) Recruiting well
Q13 Have only ever seen minor reactions to the infliximab. (Nurse) Recruiting well
Q14 We now have to request the funding for patients with UC on long-term
infliximab so that’s a bit of a challenge and it means that decisions are made
differently to whether a patient is going onto maintenance infliximab. (Nurse)
Recruiting well
Q15 It’s already an issue because we can’t really treat as maintenance with
infliximab so obviously if a patient responds well we’ve had to get exceptional
funding and things like that so there is a case for it I think. (Nurse) Recruiting
well
Personal preference and trial
involvement
Q16 My personal view is that they probably have equal efficacy, I think infliximab
has less side effects so if I was given a free choice, if I was asking for me or for
my loved ones, I would opt for infliximab. (PI) Recruiting well
Q17 When a patient was given infliximab I was rather pleased and when they were
given ciclosporin I was less enthusiastic… we wondered about the tolerance
for the patient and convenience for the patient. (PI) Recruiting well
Q18 I prefer it when they have infliximab … I think it’s easier for the patients
because it’s just one infusion…it’s a couple of hours, instead of being hooked
up. I mean keep in mind they have profuse diarrhoea… I think it’s easier to
administer as a nurse and it’s easier for the patient to receive. (Nurse)
Recruiting well
Q19 Rather more relaxed about it [ciclosporin], paradoxically, simply because I
know when the IV infusion is stopped then the drug disappears. (PI) Recruiting
well
Continued
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Nurses’ views accorded with PI opinion on this matter.
In addition, nurses were keen to emphasise the com-
plexities resulting from contextual and geographical
factors that had to be contended within a busy hospital
setting, such as managing patients on different wards or
requiring an infusion, and as a consequence the need
for a greater number of nurses with advanced prescrib-
ing capabilities on the wards at any one time: see Q3.
The practicalities of a lengthier ciclosporin infusion had
implications for patients’ well-being too, with health profes-
sionals having to spend more extensive periods of time in
hospital dealing with patients who were: ‘frustrated’ (Nurse,
recruiting well) with highly restricted movement: see Q4.
Views on the ease of administering individual drugs
were clearly inﬂuenced by an individual’s familiarity with
the drug in question. Thus, those with more experience
of ciclosporin tended to be more positive about that
drug, and they suggested that nurses should be trained
in both drugs as they faced a steep ‘learning curve’ (PI,
recruiting well), particularly in relation to ciclosporin.
Nevertheless, support for the administration of inﬂixi-
mab was more strongly felt and it was repeatedly
described as the ‘easier’ (PI, recruiting well) and more
‘convenient’ (PI, recruiting well) drug: see Q5.
While both drugs were perceived to be effective, ciclos-
porin was faster-acting, and offered a clearer patient
response timeline. Inﬂiximab, on the other hand, pre-
sented a challenge in terms of whether to continue with
it or look for a different treatment. Ciclosporin was
more ‘clear-cut’ (PI, recruiting well) and PIs felt more
conﬁdent in their decision-making and timing around
prescribing this drug. In addition, PIs worried about the
limited information available for inﬂiximab response
rates, as this did not appear to match patients’ actual
responsiveness, made all the more complex by the need
for an extended administration period: see Q6 and Q7.
In addition to response times, adverse effects were of
major importance in treating patients with one drug or
another. Ciclosporin, in particular, was seen to have a
range of associated adverse effects, which included: drug
toxicity, renal failure, neurological impairment, seizures,
tremors and hypertension. PIs were ‘uneasy’ (PI, recruiting
well) about the drug, seeing it as ‘dangerous’ (PI) poor
overall recuitment. Even those advocating its use tended to
be apprehensive about the adverse effects in the longer
term, viewing it as more of a bridging therapy. These views
were reinforced by a perceived lack of evidence of ciclos-





Q20 I’ve used it [ciclosporin] for a very long time and I’m comfortable with it. (PI)
Recruiting well
Q21 If the result was that ciclosporin was a lot better we’d use it and if the results
were that infliximab was a lot better we’d use it. (PI) Recruiting well
Q22 The difference (between drugs) is not sufficiently dramatic that I would say it
was unethical to put them into a randomised study. (PI) Recruiting well
Policy development and drug
regulation
Q23 There is an issue of cost of course, [infliximab] we’re pushed all the time to stop
it for cost reasons. (PI) Recruiting well
Q24 It’s very hard to find anyone who supports the NICE guidance in its present
format. (PI) Recruiting well
Q25 I sort of treat it with a bit of contempt. (PI) Recruiting well
Q26 You can usually find a reason why ciclosporin would be contraindicated…I
don’t think it’s a particularly sensible NICE guidance based on the lack of
evidence that they have to make their decision and therefore in all honesty
because we can, we slightly ignore it. (PI) Recruiting well
Patient benefit and
negotiated care
Q27 I like to tailor the treatment to the patient…to the patient’s previous history,
patient’s wishes (PI) Recruiting well to cohort but less well to trial
Q28 The drug we choose ultimately depends on the patient. (PI) Poor overall
recruitment
Q29 It’s whatever is best for the patient… I think it’s different for each patient and I
think that they need to be given the choice. (Nurse) Recruiting well
Q30 Our surgeons are very active in decision-making, and have multi-disciplinary
team meetings twice a week. (PI) Low overall recruitment
Q31 Care is negotiated with the patient, patient input is important, but pre-defined
pathways are according to previous discussions. (PI) Recruiting well to cohort
but less well to trial
Q32 Patient views are as important as anything else, combined with weighing up
risks and benefits, we involve them hugely. (PI) Recruiting well to cohort but
less well to trial
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An adverse risk proﬁle for ciclosporin was described as
resulting in increased patient monitoring and checking
of drug and blood levels, which, in addition to a more
resource-intensive process, impacted on nurses’ time.
This is particularly noticeable on a busy ward where
there are difﬁculties with nurse–patient ratios, and
nurses had the sense that their profession was struggling
with workload increases. This impacted on their ability
to give equal time to all patients under their care. They
reported occasionally: ‘forgetting’ (Nurse, recruiting
well) to monitor patients on ciclosporin. Inﬂiximab, on
the other hand, did not warrant any additional monitor-
ing following inpatient discharge and no issues asso-
ciated with monitoring were raised: see Q10 and Q11.
While inﬂiximab also carried a risk proﬁle that
included adverse reactions, causing particular hesitancy
in prescribing it for the older patient, it was favoured for
its perceived fewer side effects and longerterm efﬁcacy:
see Q12 and Q13.
However, PIs pointed their frustrations with policy
restrictions and Government guidelines that prevented
the use of inﬂiximab in the way they wished, including
the need to justify its use in the longer term: see Q14
and Q15.
Personal preference and trial involvement
PIs clearly recognised the effect that their own experi-
ence of using one drug or another had on their per-
sonal preference. While many were equivocal, some PIs
expressed a clear preference for inﬂiximab over ciclos-
porin based on its ease of preparation, easier administra-
tion, lower negative impact on nurse care provision,
stafﬁng and workloads, longer term beneﬁts and reduced
adverse effects. In addition, both PIs and nurses pointed
to greater patient tolerance and enhanced patient con-
venience. Further reasons for stated preferences
included: familiarity with the drug, drug effectiveness,
greater clinical expertise and knowledge, and a general
sense of ‘unease’ (PI, recruiting well) with the use of
ciclosporin: see Q16 and Q17.
Nurses’ views were similar to those of their consultant
counterparts, expressing a preference for inﬂiximab
based on its ease of administration, perceived patient
beneﬁts and personal experience and familiarity with
the drug. They highlighted the restrictions of patients
being hooked up to a ciclosporin infusion for longer
periods of time while suffering from bowel disturbances,
and noted patients’ preference for inﬂiximab in this
respect. Ciclosporin was described as ‘high mainten-
ance’ (Nurse, recruiting well): see Q18.
Two PIs described a preference for ciclosporin, based
on personal familiarity with the drug, its quicker-acting
properties and its ability to disappear from the system
once the drug administration had been halted. However,
even these two interviewees stressed the need to retain a
level of vigilance—to ‘be more wary’ (PI, poor overall
recruitment): see Q19 and Q20.
In spite of these personal preferences, there remained
a genuine sense of uncertainty as to which drug was the
more beneﬁcial at the time of the trial, particularly in
relation to people’s views of trial entry, trial manage-
ment and patient recruitment. Most healthcare profes-
sionals commented that the relative effectiveness of the
two drugs was unclear, genuinely wanting answers from
the trial team as to the ‘better’ (PI, recruiting well) of
the two. This desire was described as patient-driven,
based on which of the two was most effective and well
received by patients: see Q21 and Q22. All professionals
expressed contentment to suspend preferences within
the CONSTRUCT Trial and recognised the importance
of establishing relative effectiveness and safety.
Professionals welcomed the CONSTRUCT trial, and
congratulated the trial team for moving this body of
work forward so successfully. They discussed the fact that
they had attempted to actively recruit patients into the
trial, despite, in the lower recruiting sites, a lack of
success, which was put down to busy workloads and lack
of joined-up working patterns.
Policy development and drug regulation
Healthcare professionals were clearly aware of the higher
cost of inﬂiximab, and saw implications of this driving
policy development and guidelines for practice. Guidelines
around the use of the drug ultimately affected clinical
decision-making: see Q23.
While healthcare professionals understood the need
for rigorous guidelines around the use of the drugs,
they also linked guidelines to an enforced restriction of
the use of inﬂiximab, arguing that the NICE guidelines
(referring to TA140)21 were outdated, outmoded and
out of step with more recent evidence. This left them, as
a body of healthcare professionals, feeling frustrated and
constrained in their ability to provide the best and most
appropriate care for their patients. They described
having ‘their hands tied’ (PI, poor overall recruitment),
and believed that the more recent clinical evidence and
their own personal experience indicated inﬂiximab as
the drug that needed to be used more widely. As a con-
sequence, they urged that guidelines become more ﬂex-
ible in order to accommodate patient needs more
appropriately: see Q24 and Q25.
The point was repeatedly reinforced. While the guide-
lines were there to be adhered to, there was a clear sense
of rebellion within the profession, with clinicians ‘ignor-
ing’ (PI, recruiting well) guidelines to meet patient needs,
in order to administer inﬂiximab. Thus healthcare profes-
sionals welcomed a much-needed change to the guide-
lines that allowed for greater ﬂexibility of drug use, led
primarily from an assessment of patient need: see Q26.
Patient benefit and negotiated care
Underpinning discussions around the administration of
the drugs, treatment of patients, personal preference,
and adherence to guidelines and regulations was a pro-
fessional focus on patient beneﬁt and need. Nurses and
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PIs gave many examples of the decisions that took
account of what was best for the patient, especially when
it came to a consideration of the patient’s personal cir-
cumstances: see Q27 and Q28.
Nurses appeared more inﬂuenced than PIs by the
patient experience, perhaps as a result of their extended
contact with the patients, indicated by the fact that
nurses always discussed their preference in the context
of patient convenience and quality of life: see Q29.
As evident in quote 29, the notion of negotiated care
was central to the consultation as far as nurses were con-
cerned and ongoing patient care, and decision-making
was perceived as a shared practice across and within
multidisciplinary teams. This led to a shared professional
responsibility, while the patient–clinician interaction
came across as the ultimate example of this: see Q30,
Q31 and Q32.
DISCUSSION
Professional interviews revealed that PIs and nurses
make judgements regarding the salvage therapies largely
based on experience of giving the two drugs and percep-
tions of effectiveness and adverse side effects.
Professionals also recognised restrictions placed on
patients having continuous infusion of ciclosporin and
the ensuing frustration. Within this context, doctors
tended to favour inﬂiximab, wishing to see it as the drug
of choice in view of its ability to deal with the many
complex symptoms this disease group displays, fewer
side effects, greater familiarity, greater effectiveness and
ease of handling. Such factors have been recognised as
inﬂuencing doctors’ prescribing habits for new drugs in
the existing literature22 and clearly inﬂuenced which
drug professionals prefer within this study.
Ciclosporin was presented as more complex and cum-
bersome to deliver, which required additional monitor-
ing which tended to be particularly problematic on busy
wards with extensive demands on an already over-
stretched healthcare professional workforce. This led to
nurses presenting a clear preference for inﬂiximab.
Furthermore, ciclosporin was considered excessively
demanding of specialist nurses’ and other healthcare
professionals’ time, who need to be present to manage
any complications and the drug’s adverse risk proﬁle
required a greater perceived need for more intensive
patient monitoring. This is a matter of concern in the
light of contemporary reports regarding patient care
and safety implications of overworked and understaffed
hospitals and is contrary to recommendations to
increase the support provided by non-medical
professionals.23
Consequently, professionals questioned the current
NICE guidelines (TA140)21 and government regulations
around drug use, and PIs presented a sense of unease
about the restrictions placed on their personal auton-
omy in prescribing inﬂiximab to patients with acute UC
who failed to respond to conventional therapies.
Professionals were keen to change the regulations sur-
rounding current prescribing and drug administration,
and they also wanted changes to be implemented
regarding longer term patient maintenance, with many
preferring inﬂiximab as the longer term drug of choice.
The current literature on inﬂammatory bowel disease
(IBD) and associated diseases24 25 supports this view,
describing the disease group as displaying particularly
complex activity and requiring a range of tools and treat-
ment algorithms to assess symptoms and treat appropri-
ately. Consequently, these professionals were keen to
understand the individual patient’s perspective as to how
the disease affects their life. The literature suggests that
such an understanding is closely aligned to the patient’s
health and social care needs and therefore should not
be overlooked25 26 To take account of individual per-
spectives, professionals recommended good communica-
tion, including shared decision-making over symptom
relief and drug prescribing. The literature endorses this
ﬁnding, highlighting the value of close empathic profes-
sional support for patients with IBD and other related
diseases27 and emphasises the extensive psychosocial
concomitants of this illness group, including a positive
association with poorer perception of health and well-
being and poorer psychological function.28
Strengths and limitations
The results of this qualitative interview study indicate the
importance of incorporating qualitative data within clin-
ical trials and how a deeper understanding of health
professionals’ views can clarify clinical data about drug
treatment and drug preference. This includes how pre-
ferences can affect or, in this case, not affect equipoise
and participation in the trial. Interviews with PIs and
nurses who were treating participants in a large UK-wide
randomised controlled trial to collect rich, complemen-
tary and comprehensive data contributed to the study’s
aims and objectives. Qualitative data came from intervie-
wees in a broad mix of participating sites (recruiting
well to cohort and trial, recruiting well to cohort but less
well to trial and those recruiting poorly to both the
cohort and trial). The data collected provided an under-
standing of healthcare professionals’ perspectives on
patient recruitment and the two drugs. Interviews have
illuminated valuable professional perspectives, ﬁlled
gaps in our knowledge base about personal views and
experiences of the two salvage drugs within UC and pro-
vided joined-up trial outputs and ideas for follow-on
qualitative research with further trial professionals.
This study has its limitations; whereas qualitative
research does not seek population representativeness or
provide generalisable ﬁndings, the small interview
numbers could be considered a limitation and without
an extension to the sample size, to include further
healthcare professionals who recruited for the cohort
and the trial, we cannot make claims for the overall
views of the professional trial group. Nor can our claims
about patient recruitment, trial success, shared decision-
Clement C, et al. BMJ Open 2017;7:e014512. doi:10.1136/bmjopen-2016-014512 7
Open Access
making and drug equipoise be transferable across all
trial sites. For this, further interviews are needed to use-
fully build on these data to take ﬁndings forward. Future
research should focus on exploring ﬁndings from this
study across a greater number and wide range of trial
sites. It would also be beneﬁcial to explore, following
publication of the main trial ﬁndings, how views may
have changed in the light of equal effectiveness across
the two trial drugs being shown.29 How will this inﬂu-
ence the preferences stated here and will it affect profes-
sionals’ decision-making between the two?
CONCLUSION
To conclude, this paper has highlighted strong health-
care professional support for inﬂiximab as salvage treat-
ment for patients with acute severe UC who fail to
respond to steroids, largely based on the resource-
intensive nursing requirements for the intravenous
administration of ciclosporin. However, in spite of drug
preferences in some, professionals were happy to
suspend any such preferences while participating in the
trial and recognised the importance of establishing rela-
tive effectiveness and safety. It is apparent that profes-
sionals were inﬂuenced by their own personal familiarity
with the drug and considerations of its perceived effect-
iveness and beneﬁt for patients. They are also swayed by
their views of others’ ability to manage drugs, and their
effectiveness in the longer term for patient health and
well-being. Nevertheless, professionals are keen to seek
answers to questions from the trial as to which is the
more beneﬁcial of the two drugs, seeing the trial as a
vital step towards providing the information necessary to
take practice forward. For the time being, at least, pro-
fessionals will continue to uphold their own practices,
circumventing the rules and regulations to some extent,
in order to offer patients their drug of choice.
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